Abstract
SummarySpurred by devoted research and institutional financing, organ replacement therapies have progressed monumentally over the last century. Concomitantly, there has been an escalation in healthcare costs. In an aging society where organ replacement therapy utilization is expected to continue to rise, will society need to rethink the economics of end‐stage organ dysfunction management?
Subject
Biomedical Engineering,General Medicine,Biomaterials,Medicine (miscellaneous),Bioengineering
Reference5 articles.
1. Medicare's end stage renal disease program;Eggers PW;Health Care Financ Rev,2000
2. Evolution of Cardiopulmonary Bypass
3. Globe Newswire.Global tempered glass market to reach $201.7 billion by 2030. Available from:https://www.globenewswire.com/en/news‐release/2023/05/04/2661911/0/en/Global‐Tempered‐Glass‐Market‐to‐Reach‐201‐7‐Billion‐by‐2030.html
4. Current status and future directions in the development and optimization of thoracic and abdominal artificial organs